1. Home
  2. EVH vs IMMX Comparison

EVH vs IMMX Comparison

Compare EVH & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evolent Health Inc

EVH

Evolent Health Inc

HOLD

Current Price

$2.76

Market Cap

344.8M

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$7.41

Market Cap

306.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVH
IMMX
Founded
2011
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
344.8M
306.2M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
EVH
IMMX
Price
$2.76
$7.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
2
Target Price
$10.67
$13.00
AVG Volume (30 Days)
3.2M
963.5K
Earning Date
02-24-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,054,052,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$26.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.56
$1.34
52 Week High
$12.07
$7.73

Technical Indicators

Market Signals
Indicator
EVH
IMMX
Relative Strength Index (RSI) 28.46 68.55
Support Level $2.56 $6.02
Resistance Level $2.91 $7.04
Average True Range (ATR) 0.20 0.61
MACD -0.03 0.14
Stochastic Oscillator 21.08 84.67

Price Performance

Historical Comparison
EVH
IMMX

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: